The phosphatidylserine targeting antibody bavituximab plus pembrolizumab in unresectable hepatocellular carcinoma: a phase 2 trial

MLA

David Hsiehchen, et al. “The Phosphatidylserine Targeting Antibody Bavituximab plus Pembrolizumab in Unresectable Hepatocellular Carcinoma: A Phase 2 Trial.” Nature Communications, vol. 15, no. 1, Mar. 2024, pp. 1–10. EBSCOhost, https://doi.org/10.1038/s41467-024-46542-y.

APA

David Hsiehchen, Muhammad S. Beg, Radhika Kainthla, Jay Lohrey, Syed M. Kazmi, Leticia Khosama, Mary Claire Maxwell, Heather Kline, Courtney Katz, Asim Hassan, Naoto Kubota, Ellen Siglinsky, Anil K. Pillai, Hagop Youssoufian, Colleen Mockbee, Kerry Culm, Mark Uhlik, Laura Benjamin, Rolf A. Brekken, … Adam C. Yopp. (2024). The phosphatidylserine targeting antibody bavituximab plus pembrolizumab in unresectable hepatocellular carcinoma: a phase 2 trial. Nature Communications, 15(1), 1–10. https://doi.org/10.1038/s41467-024-46542-y

Chicago

David Hsiehchen, Muhammad S. Beg, Radhika Kainthla, Jay Lohrey, Syed M. Kazmi, Leticia Khosama, Mary Claire Maxwell, et al. 2024. “The Phosphatidylserine Targeting Antibody Bavituximab plus Pembrolizumab in Unresectable Hepatocellular Carcinoma: A Phase 2 Trial.” Nature Communications 15 (1): 1–10. doi:10.1038/s41467-024-46542-y.